Global Primary Immunodeficiency Therapeutics Market to Reach $12.9 Billion by 2030
The global market for Primary Immunodeficiency Therapeutics estimated at US$7.8 Billion in the year 2022, is projected to reach a revised size of US$12.9 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2022-2030. Antibody Deficiency, one of the segments analyzed in the report, is projected to record 7.1% CAGR and reach US$7.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellular Immunodeficiency segment is readjusted to a revised 5.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 5.9% CAGR
The Primary Immunodeficiency Therapeutics market in the U.S. is estimated at US$2.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 5.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.Select Competitors (Total 47 Featured) -
- CSL Behring
- Grifols International SA
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Primary Immunodeficiency Diseases - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Primary Immunodeficiency Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for Primary Immunodeficiency Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for Primary Immunodeficiency Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for Antibody Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for Cellular Immunodeficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Innate Immune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Immunoglobuline Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Immunoglobuline Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Immunoglobuline Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Antibiotic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Stem Cell & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Stem Cell & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Stem Cell & Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 29: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 35: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- JAPAN
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 41: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- CHINA
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 44: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 47: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- EUROPE
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Primary Immunodeficiency Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Primary Immunodeficiency Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- FRANCE
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 59: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 62: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- GERMANY
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- ITALY
- Table 71: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Rest of Europe 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Primary Immunodeficiency Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Asia-Pacific 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 95: Rest of World Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Primary Immunodeficiency Therapeutics by Disease Type - Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Rest of World 16-Year Perspective for Primary Immunodeficiency Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders for the Years 2014, 2023 & 2030
- Table 98: Rest of World Recent Past, Current & Future Analysis for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Primary Immunodeficiency Therapeutics by Treatment Type - Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Primary Immunodeficiency Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- CSL Behring
- Grifols International SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 197 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 7.8 Billion |
Forecasted Market Value ( USD | $ 12.9 Billion |
Compound Annual Growth Rate | 6.5% |
Regions Covered | Global |